- Home
- BMA vs GH Comparison
BMA vs GH Comparison
Compare BMA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- GH
- Stock Information
- Founded
- BMA 1966
- GH 2011
- Country
- BMA Argentina
- GH United States
- Employees
- BMA N/A
- GH N/A
- Industry
- BMA Commercial Banks
- GH Medical Specialities
- Sector
- BMA Finance
- GH Health Care
- Exchange
- BMA Nasdaq
- GH Nasdaq
- Market Cap
- BMA 4.2B
- GH 4.9B
- IPO Year
- BMA 2006
- GH 2018
- Fundamental
- Price
- BMA $44.21
- GH $56.68
- Analyst Decision
- BMA Hold
- GH Strong Buy
- Analyst Count
- BMA 3
- GH 17
- Target Price
- BMA $50.75
- GH $58.24
- AVG Volume (30 Days)
- BMA 709.4K
- GH 2.3M
- Earning Date
- BMA 08-27-2025
- GH 11-05-2025
- Dividend Yield
- BMA 1.70%
- GH N/A
- EPS Growth
- BMA N/A
- GH N/A
- EPS
- BMA 0.50
- GH N/A
- Revenue
- BMA $2,573,417,306.00
- GH $828,849,000.00
- Revenue This Year
- BMA N/A
- GH $28.07
- Revenue Next Year
- BMA $11.90
- GH $21.61
- P/E Ratio
- BMA $8.77
- GH N/A
- Revenue Growth
- BMA N/A
- GH 28.74
- 52 Week Low
- BMA $42.17
- GH $20.14
- 52 Week High
- BMA $118.42
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- BMA 29.78
- GH 47.38
- Support Level
- BMA $42.17
- GH $53.40
- Resistance Level
- BMA $48.05
- GH $61.95
- Average True Range (ATR)
- BMA 2.87
- GH 2.39
- MACD
- BMA -0.88
- GH -1.27
- Stochastic Oscillator
- BMA 10.73
- GH 22.47
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.